Lessons From Red Yeast Rice May Inform FDA's Path For CBD

By Greg Kaufman, Meghana Shah and Amber Unwala (May 28, 2019, 12:57 PM EDT) -- As the cannabis industry grows, all eyes are on the U.S. Food and Drug Administration to define its regulation and enforcement approach to products containing cannabidiol. CBD derived from cannabis plants has been touted for its therapeutic properties.[1] How the FDA will choose to regulate CBD remains uncertain. Will the FDA look at prior precedent involving red yeast rice,[2] an infamous decision in the eye of the dietary supplement industry, and what influence may this precedent have on their decision-making regarding CBD?...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!